Reduction of Tumor Necrosis Factor Production by Splenocytes from V-Ha-ras Oncogene-bearing Mice

Overview

Journal Cancer Lett

Specialty Oncology

Date 1993 Nov 1

PMID 7513605

Authors

G J Chen

L L Colombo

M C Lopez

R R Watson

Affiliations

Soon will be listed here.

Abstract

Mice containing the activated v-Ha-ras oncogene driven by the mouse mammary tumor virus promoter/enhancer produced less tumor necrosis factor (TNF) than genetically identical animals without it. Inbred Oncomice containing the v-Ha-ras oncogene and inbred FVB mice without it were grown for 6 months. Splenocytes were isolated and stimulated in vitro to produce tumor necrosis factor (TNF) and gamma-interferon (IFN). TNF production by cells from Oncomice was significantly decreased compared to cells from FBV mice. There was a tendency for decrease, but no significant difference was seen on IFN release. These observations suggest that the oncogene may play a role in the immune system.

References

Grunfeld C, Palladino Jr M . Tumor necrosis factor: immunologic, antitumor, metabolic, and cardiovascular activities. Adv Intern Med. 1990; 35:45-71. View

Teitelman G, Alpert S, Hanahan D . Proliferation, senescence, and neoplastic progression of beta cells in hyperplasic pancreatic islets. Cell. 1988; 52(1):97-105. DOI: 10.1016/0092-8674(88)90534-x. View

Chen G, Watson R . Modulation of tumor necrosis factor and gamma interferon production by cocaine and morphine in aging mice infected with LP-BM5, a murine retrovirus. J Leukoc Biol. 1991; 50(4):349-55. DOI: 10.1002/jlb.50.4.349. View

Hanahan D . Transgenic mice as probes into complex systems. Science. 1989; 246(4935):1265-75. DOI: 10.1126/science.2686032. View

Palladino Jr M, Shalaby M, Kramer S, Ferraiolo B, Baughman R, DeLeo A . Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol. 1987; 138(11):4023-32. View

Stewart T, Pattengale P, Leder P . Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell. 1984; 38(3):627-37. DOI: 10.1016/0092-8674(84)90257-5. View

Creasey A, Reynolds M, Laird W . Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res. 1986; 46(11):5687-90. View

Kramer S, Aggarwal B, Eessalu T, McCabe S, Ferraiolo B, Figari I . Characterization of the in vitro and in vivo species preference of human and murine tumor necrosis factor-alpha. Cancer Res. 1988; 48(4):920-5. View

Hansen M, Cavenee W . Genetics of cancer predisposition. Cancer Res. 1987; 47(21):5518-27. View

10.

Sugimoto Y, Ikawa Y, Nakauchi H . Thy-1 as a negative growth regulator in ras-transformed mouse fibroblasts. Cancer Res. 1991; 51(1):99-104. View

11.

Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P . Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell. 1987; 49(4):465-75. DOI: 10.1016/0092-8674(87)90449-1. View

12.

Asher A, Mule J, Reichert C, Shiloni E, Rosenberg S . Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol. 1987; 138(3):963-74. View

13.

Hanahan D . Dissecting multistep tumorigenesis in transgenic mice. Annu Rev Genet. 1988; 22:479-519. DOI: 10.1146/annurev.ge.22.120188.002403. View

14.

Haranaka K, Satomi N, Sakurai A . Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer. 1984; 34(2):263-7. DOI: 10.1002/ijc.2910340219. View